Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00817414 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Effects of LCI699 on Cortisol in Participants With Hypertension
A Phase 2 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
NCT00817414 is a Phase 2 study that has completed, run by Novartis. The registered enrollment target is 63 participants.
The verdict
NCT00817414, a Phase 2 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
Study Summary
This study determined the maximum dose of LCI6999 with respect to effect on the ACTH-stimulated cortisol response in participants with hypertension.
Interventions
- DRUG LCI699
- DRUG LCI699-matching placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2009-01-14 |
| Est. Completion | 2009-08-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00817414
The ClinicalTrials.gov registry entry for NCT00817414 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LCI699 is the first listed.
NCT00817414 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00817414 about?
NCT00817414 is a clinical study titled "A Study to Evaluate the Effects of LCI699 on Cortisol in Participants With Hypertension". This study determined the maximum dose of LCI6999 with respect to effect on the ACTH-stimulated cortisol response in participants with hypertension.
What is the current status of trial NCT00817414?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2009-01-14. Estimated completion is 2009-08-12.
What interventions are being tested in trial NCT00817414?
The interventions under investigation include: LCI699 (DRUG), LCI699-matching placebo (DRUG).
Who is sponsoring clinical trial NCT00817414?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.